Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.
Research on the Therapeutic Effect and Clinical Indicators of XingpiJieyu Formula in the Treatment of Severe Liver Depression and Spleen Deficiency Type Depression Based on Abnormal Mitochondrial Energy Metabolism Pathway
Study Title: Research on the therapeutic effect and clinical indicators of XingpiJieyu formula in the treatment of severe liver depression and spleen deficiency type depression based on abnormal mitochondrial energy metabolism pathway
Purpose of the Study: (1) Application of XPJYF in the treatment of severe MDD patients for 8 weeks, detection of abnormal mitochondrial energy metabolism and biosynthesis, and exploration of biological markers for the therapeutic effect of XPJYF in the treatment of severe MDD with liver depression and spleen deficiency type. (2) Explore the biological indicators for predicting the antidepressant efficacy of XPJYF in the treatment of severe MDD patients and explore new pharmacological pathways for the combination of traditional Chinese and Western medicine in the treatment of MDD.
To evaluate whether adding Xingpi Jieyu Formula (a traditional Chinese herbal granule) to the standard antidepressant escitalopram improves symptoms in people with severe major depressive disorder (MDD) who also have a specific traditional Chinese medicine pattern called "Liver-Stagnation and Spleen-Deficiency."
Study Design:
100 patients with severe MDD (Liver-Stagnation and Spleen-Deficiency pattern) will be randomly assigned to one of two groups: Test group: Escitalopram + Xingpi Jieyu Formula, Control group: Escitalopram + placebo (identical granules with no active ingredient).
An additional 50 healthy volunteers will serve as a comparison group. Treatment duration: 8 weeks. Double-blind design: neither participants nor study doctors know who receives the real herbal formula or the placebo.
Data Collection Timepoints: Baseline (before treatment), Week 2, and Week 8 (end of treatment). At each timepoint, blood samples and clinical information (e.g., mood ratings, symptom scores) will be collected.
Main Measurements: Blood samples will be tested for markers of mitochondrial energy metabolism (using ELISA). Whole genome testing will be performed in 60 patients (from the MDD groups) and in all 30 healthy volunteers.
Inclusion Criteria: ① Outpatient/inpatient, aged 18-60, right-handed. ② The diagnosis of Western medicine meets the diagnostic criteria of DSM-5 for MDD, as well as the diagnostic criteria for depression and liver depression and spleen deficiency in the 2008 Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine issued by the Chinese Society of Traditional Chinese Medicine HAMD-17 score ≥ 18 points, and HAMD-17 item 3 ≤ 2 points
Exclusion Criteria: ① DSM-5, with the exception of MDD, has any current or past diagnosis of Axis I mental disorders (MINI). Or it does not meet the diagnostic criteria for depression and liver depression and spleen deficiency syndrome in the "Diagnosis and Treatment Guidelines for Common Diseases in Traditional Chinese Medicine" issued by the Chinese Society of Traditional Chinese Medicine in 2008. ② Education years<5 years or IQ<90 points. ③ Suicide ideation or suicidal behavior (HAMD-17 item 3>2 points).
Possible Benefits: May offer a new treatment option for patients with severe depression who do not fully respond to standard antidepressants. May help identify blood markers that can predict which patients are most likely to benefit from adding traditional Chinese medicine to their treatment. May improve understanding of how traditional Chinese medicine affects cellular energy metabolism (mitochondria), potentially leading to better treatments for depression.
Risks and Safety: All study medications (escitalopram and Xingpi Jieyu Formula) are already approved for clinical use. Side effects are known and generally mild. Blood draws may cause temporary discomfort or bruising. Participants will be closely monitored by study doctors. If serious side effects occur, the study medication can be stopped and appropriate medical care will be provided. All personal information and test results will be kept confidential.
Study Location and Approval: This study is led by researchers at Peking University Sixth Hospital (and other collaborating centers) and has been approved by the Medical Ethics Committee.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 100191
- Peking University Sixth Hospital
-
Beijing, Kina
- Peking University Sixth Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
① Outpatient/inpatient, aged 18-60, right-handed
② The diagnosis of Western medicine meets the diagnostic criteria of DSM-5 for MDD, as well as the diagnostic criteria for depression and liver depression and spleen deficiency in the 2008 Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine issued by the Chinese Society of Traditional Chinese Medicine HAMD-17 score ≥ 18 points, and HAMD-17 item 3 ≤ 2 points
Exclusion criteria:
- DSM-5, with the exception of MDD, has any current or past diagnosis of Axis I mental disorders (MINI). Or it does not meet the diagnostic criteria for depression and liver depression and spleen deficiency syndrome in the "Diagnosis and Treatment Guidelines for Common Diseases in Traditional Chinese Medicine" issued by the Chinese Society of Traditional Chinese Medicine in 2008 ② Education years<5 years or IQ<90 points ③ Suicide ideation or suicidal behavior (HAMD-17 item 3>2 points)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: XingpiJieyu Formula + Escitalopram
Patients with severe major depressive disorder (Liver-Stagnation and Spleen-Deficiency pattern according to TCM) receive oral escitalopram (10-20 mg/day) combined with XingpiJieyu Formula granules for 8 weeks.
|
XingpiJieyu Formula (XPJYF): Traditional Chinese medicine herbal granules. Dosage: 1 sachet (approximately 5 g) taken orally with 200 ml warm water after meals, twice daily. Escitalopram: Selective serotonin reuptake inhibitor (SSRI) tablets. Dosage: 10 mg/day for the first week; after one week, the dose may be increased to 10-20 mg/day based on clinical response and tolerability. Both medications are taken for 8 weeks. |
|
Placebo komparator: XingpiJieyu Placebo + Escitalopram
Patients with severe major depressive disorder (Liver-Stagnation and Spleen-Deficiency pattern according to TCM) receive oral escitalopram (10-20 mg/day) combined with a matching placebo for 8 weeks.
|
XingpiJieyu Placebo: Granules identical in appearance, taste, and administration to Xingpi Jieyu Formula but containing no active pharmaceutical ingredients. Dosage: 1 sachet taken orally with 200 ml warm water after meals, twice daily. Escitalopram: Same as Arm 1 (10-20 mg/day for 8 weeks). |
|
Ingen inngripen: Healthy Control
Age- and sex-matched healthy volunteers receive no medication.
They undergo the same blood sample collection and clinical assessments at baseline.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SIRT1 and its mRNA in peripheral blood nucleated cells
Tidsramme: Baseline (week 0), week 2, and week 8
|
Detection of SIRT1 and its mRNA in peripheral blood nucleated cells (particularly PBMCs) at the end of 8 weeks treatment from baseline and compared with healthy control on baseline to test biological effectiveness of XPJYF and ESC in the treatment of MDD.
|
Baseline (week 0), week 2, and week 8
|
|
Hamilton Depression Rating Scale, 17 items (HAMD-17) total score changes
Tidsramme: Baseline (week 0), week 2, and week 8
|
One hundred MDD patients with treatment - efficacy as assessed by HAMD - 17 on baseline, at the end of 2 weeks and 8 weeks.
|
Baseline (week 0), week 2, and week 8
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
TESS for adverse effect rating
Tidsramme: Week 2 and week 8
|
TESS assessment was used to evaluate the adverse effects of XPJYF and ESC treatment in 80 patients with MDD at the end of 2 weeks and 8 weeks of treatment, and the difference in total TESS scores between the two MDD groups (40 patients in each group) was compared.
|
Week 2 and week 8
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- MR-11-23-049173
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .